Amgen Inc (AMGN)

AMGN (NASDAQ:Drugs) EQUITY
$159.60
pos +0.00
+0.00%
Today's Range: 0.00 - 0.00 | AMGN Avg Daily Volume: 3,615,700
Last Update: 03/05/15 - 3:59 PM EST
Volume: 0
YTD Performance: 0.19%
Open: $0.00
Previous Close: $159.60
52 Week Range: $108.20 - $173.14
Oustanding Shares: 758,861,306
Market Cap: 120,803,131,302
6-Month Chart
TheStreet Ratings Grade for AMGN
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 6 5 5 5
Moderate Buy 2 2 2 2
Hold 8 8 7 7
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2.09 2.17 2.11 2.11
Latest Dividend: 0.79
Latest Dividend Yield: 1.98%
Dividend Ex-Date: 02/10/15
Price Earnings Ratio: 23.76
Price Earnings Comparisons:
AMGN Sector Avg. S&P 500
23.76 23.80 27.74
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-5.70% 26.48% 137.39%
GROWTH 12 Mo 3 Yr CAGR
Revenue 7.40 0.29 0.09
Net Income 1.50 0.40 0.12
EPS 0.90 0.67 0.18
Earnings for AMGN:
EBITDA 8.74B
Revenue 20.06B
Average Earnings Estimates
Qtr (03/15) Qtr (06/15) FY (12/15) FY (12/16)
Average Estimate $2.09 $2.38 $9.36 $10.53
Number of Analysts 10 9 13 11
High Estimate $2.40 $2.45 $9.75 $11.23
Low Estimate $1.95 $2.29 $9.21 $10.08
Prior Year $1.86 $2.37 $8.68 $9.36
Growth Rate (Year over Year) 12.20% 0.61% 7.81% 12.52%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands

updateCowen Healthcare Conf.

Mar 2, 2015 | 7:50 AM EST

Cowen Health Care Conference (Day 1 of 3) - 03/02/15 - 03/04/15 Boston, M

By

TheStreet

 | Feb 4, 2015 | 1:45 PM EST

The debate raging among investors about hepatitis C revenue declines.

By

Timothy Collins

 | Jan 8, 2015 | 10:09 AM EST
Do you need to pick one name?
By

Kate Stalter

 | Jan 6, 2015 | 12:00 PM EST

They are prone to being whipsawed by news.

updateAmgen rated new Equal-weight at Barclays

Jan 6, 2015 | 7:48 AM EST

AMGN was initiated with an Equal-weight rating, Barclays said. Company will struggle to sustain the momentum from 2014. $180 price target. 

bearishAmgen downgraded at Morgan Stanley

Jan 5, 2015 | 6:34 AM EST

AMGN was downgraded to Equal-weight from Overweight, Morgan Stanley said. $177 price target. Valuation call, as the company lacks near-term catalysts.  

By

Timothy Collins

 | Dec 22, 2014 | 3:26 PM EST

Every trade should have a thesis and a catalyst.

By

Timothy Collins

 | Dec 16, 2014 | 3:48 PM EST

Why I'm looking at the iShares Biotech ETF and Amgen.

By

Jim Cramer

 | Dec 8, 2014 | 5:08 AM EST

A litany of reasons why you should calm your nerves.

By

Jim Cramer

 | Dec 2, 2014 | 11:38 AM EST

In this era of turmoil, investors can take comfort in this sector.

Weyerhaeuser (WY) is seeing further weakness after penetrating the channel support I noted...
Blow off highs tend to take place on significant news days. In recent years, the monthly ...
Market trying to hold on to minor gains as we head into the close. Equities have been in ...
Shares near $4 and a buyer paid 50c for nearly 1500 Sep 5 calls to open a new position 25%...

REAL MONEY PRO'S BEST IDEAS

Columnist Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.